# A Phase 1 Trial of OPB-111077 in Combination With Bendamustine and Rituximab in Patients With r/r DLBCL

> **NCT04049825** · PHASE1 · COMPLETED · sponsor: **Otsuka Pharmaceutical Co., Ltd.** · enrollment: 36 (actual)

## Conditions studied

- Relapsed or Refractory Diffuse Large B-cell Lymphoma

## Interventions

- **DRUG:** OPB-111077
- **DRUG:** OPB-111077

## Key facts

- **NCT ID:** NCT04049825
- **Lead sponsor:** Otsuka Pharmaceutical Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-11-22
- **Primary completion:** 2025-03-25
- **Final completion:** 2026-01-19
- **Target enrollment:** 36 (ACTUAL)
- **Last updated:** 2026-04-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04049825

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04049825, "A Phase 1 Trial of OPB-111077 in Combination With Bendamustine and Rituximab in Patients With r/r DLBCL". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT04049825. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*